However, altered biomarkers of inflammatory and endothelial function, increased purinergic receptor expression, and exacerbated oxidative stress lead to possible targets for the treatment of CAN. This evidence concerns the gene P2RX3 and Crouzon syndrome-acanthosis nigricans syndrome.